Clinical Grade Molecular Profiling Of Patients With Multiple Myeloma And Related Plasma Cell Malignancies Read more
A Phase 2B Study Of Selinexor (KPT-330), In Combination With Carfilzomib, Daratumumab Or Pomalidomide In Patients With Multiple Myeloma Relapsing On Current Therapy Read more
A Phase 1b/2 Study Of Selinexor (KPT-330) In Combination With Backbone Treatments For Relapsed/Refractory Multiple Myeloma Read more
Myeloma-Developing Regimens Using Genomics (Mydrug) (Genomics Guided Multi-Arm Trial Of Targeted Agents Alone Or In Combination With A Backbone Regimen) Read more
A Phase I/II Assessment Of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) And Anti-TGIT (BMS-986207) Read more
A Phase 1/2 Open-Label Study To Investigate The Safety And Tolerability, Efficacy, Pharmacokinetics, And Immunogenicity Of TAK-573 As A Single Agent In Patients With Refractory Multiple Myeloma Read more
A Phase I In Human Study Evaluating The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AMG 176 In Subjects With Relapsed Or Refractory Multiple Myeloma Read more
A Single-Arm, Open-Label, Phase 1 Study Of The Safety, Efficacy, And Cellular Kinetics/Pharmacodynamics Of ALLO-715 To Evaluate An Anti-BCMA Allogeneic CAR T Cell Therapy In Subjects With Relapsed/Refractory Multiple Myeloma Read more
